# SYS6023

Source: https://onco.cc/drugs/sys6023/  
OnCo record `sys6023` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SYS6023 is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER3.

## Summary

SYS6023 is an antibody-drug conjugate developed by CSPC Megalith Biopharmaceutical. Its target is HER3 (the sponsor names HER3). The sponsor states: Antibody-drug conjugate targeting HER3, administered by intravenous infusion. ClinicalTrials.gov describes the intervention as: SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in HR-positive / HER2-negative breast cancer. The largest, NCT07597629, plans to enrol 36 participants with primary completion expected 2027-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Antibody-drug conjugate targeting HER3, administered by intravenous infusion.

## Sources

- ClinicalTrials.gov: trials of SYS6023: https://clinicaltrials.gov/search?intr=SYS6023

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- targets: [HER3](https://onco.cc/targets/her3/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- trials: [A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer](https://onco.cc/trials/nct07597629/)

---
JSON: https://onco.cc/api/v1/entities/sys6023.json